Europe Bipolar Disorder Market

Europe Bipolar Disorder Market Size

The bipolar disorder market size in Europe was valued at USD 0.83 billion in 2024. The European market is estimated to be worth USD 1 billion by 2033 from USD 0.85 billion in 2025, growing at a CAGR of 2.12% from 2025 to 2033.

MARKET DRIVERS

Increasing Incidence of Bipolar Disorders

Growing incidence of bipolar disorders, unmet medical needs, strong pipeline drugs organized by pharmaceutical industries an unhealthy lifestyle of people is majorly increasing the growth of the market in the European region. An estimated 46 million people are diagnosing bipolar disorders globally, in which 52% of males and 48% are female. Technological advancements, a growing number of initiatives taken by the European governments to create awareness among people, and rising government support through funds and investments are positive signals co-operating to develop further. For instance, the introduction of the bipolar disorder phenomena database, sponsored by the National Institute of Mental Health (NIMH), provides full research information regarding the disorder's visible signs and complaints.

MARKET RESTRAINTS

Insufficient Diagnostic Amenities

Insufficient amenities for bipolar disorder diagnosis, incapable equipment resulting in bipolar disorder, stringent government rules on misrecognition of the disorder, and inadequate equipment resulting in bipolar disorder being written as other personality disorder or depression. Rising adverse side-effects post to the usage of drugs during the treatment of disease, restraining the market growth in the region.

REPORT COVERAGE

REGIONAL ANALYSIS

Europe is next to North America in governing the global bipolar disorder market. It is predicted to grow at a prominent rate during the forecast period due to technological advancements, growing awareness associated with bipolar disorder, and healthcare infrastructure advancements. 

Germany and the UK are expected to have notable growth from 2023 to 2028 due to the Y-O-Y increase in bipolar disorders. Technological advancements have been used in developing genetic research on bipolar disorder and further augmenting the market. Growing awareness related to bipolar disorders, a growing number of mergers and acquisitions among drug-producing companies are fueling the market region. France, Italy, and Spain hold a significant share in the bipolar disorder market in Europe. 

The increasing awareness about bipolar disorder and the region's developed healthcare infrastructure is expected to be a significant driver of market growth.

KEY MARKET PLAYERS

Lead players in the market are Gedeon Richter, Indivior, AstraZeneca, Janssen Pharmaceuticals, Lundbeck, Bristol-Myers Squibb, Otsuka Holdings Co. Ltd., Glaxo SmithKline (GSK), Allergan Plc, Pfizer, Inc., and AbbVie, Inc.

MARKET SEGMENTATION

This Europe bipolar disorder market research report is segmented and sub-segmented into the following categories.

By Type

• Bipolar I Disorder
• Bipolar II Disorder
• Cyclothymic Disorder

By Mechanism of Action

• Monoamine Oxidase Inhibitors
• Tricyclic Antidepressants
• Benzodiazepines
• Serotonin-Norepinephrine Reuptake Inhibitors
• Beta-Blockers
• Selective Serotonin Reuptake Inhibitors
• Others

By Drug Class

• Antianxiety Drugs
• Mood Stabilizers
• Antidepressant Drugs
• Antipsychotic Drugs
• Anticonvulsants

By Country

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe